Trial set for May 15 in EPO patent dispute. Amgen claims TKT's gene-activated erythropoietin infringes its Epogen patents (1"The Pink Sheet" April 3, p. 7). Judge William Young will hear the case in Boston federal court
You may also be interested in...
Transkaryotic Therapies may have an enablement argument against Amgen's patents for erythropoietin, Judge William Young said during a hearing held March 27-28 in Boston federal court to define claims included in the EPO marketer's patents.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials